Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Ergometrine stability in postpartum haemorrhage kits: Does temperature and light matter?

Donnan F, Senarathna SMDKG, Ware B, Rawlins MDM, Dontham C, Chuang VTG, Batty KT.

Aust N Z J Obstet Gynaecol. 2019 Sep 11. doi: 10.1111/ajo.13046. [Epub ahead of print]

PMID:
31512230
2.

Cell-penetrating mechanism of intracellular targeting albumin: Contribution of macropinocytosis induction and endosomal escape.

Ichimizu S, Watanabe H, Maeda H, Hamasaki K, Ikegami K, Chuang VTG, Kinoshita R, Nishida K, Shimizu T, Ishima Y, Ishida T, Seki T, Katsuki H, Futaki S, Otagiri M, Maruyama T.

J Control Release. 2019 Jun 28;304:156-163. doi: 10.1016/j.jconrel.2019.05.015. Epub 2019 May 10.

PMID:
31082432
3.

Distribution of Polysulfide in Human Biological Fluids and Their Association with Amylase and Sperm Activities.

Ikeda M, Ishima Y, Chuang VTG, Sakai M, Osafune H, Ando H, Shimizu T, Okuhira K, Watanabe H, Maruyama T, Otagiri M, Akaike T, Ishida T.

Molecules. 2019 Apr 30;24(9). pii: E1689. doi: 10.3390/molecules24091689.

4.

Benzbromarone Attenuates Oxidative Stress in Angiotensin II- and Salt-Induced Hypertensive Model Rats.

Muraya N, Kadowaki D, Miyamura S, Kitamura K, Uchimura K, Narita Y, Miyamoto Y, Chuang VTG, Taguchi K, Maruyama T, Otagiri M, Hirata S.

Oxid Med Cell Longev. 2018 Jun 5;2018:7635274. doi: 10.1155/2018/7635274. eCollection 2018.

5.

Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions.

Minayoshi Y, Maeda H, Yanagisawa H, Hamasaki K, Mizuta Y, Nishida K, Kinoshita R, Enoki Y, Imafuku T, Chuang VTG, Koga T, Fujiwara Y, Takeya M, Sonoda K, Wakayama T, Taguchi K, Ishima Y, Ishida T, Iwakiri Y, Tanaka M, Sasaki Y, Watanabe H, Otagiri M, Maruyama T.

Drug Deliv. 2018 Nov;25(1):1067-1077. doi: 10.1080/10717544.2018.1464083.

6.

Design and tuning of a cell-penetrating albumin derivative as a versatile nanovehicle for intracellular drug delivery.

Ichimizu S, Watanabe H, Maeda H, Hamasaki K, Nakamura Y, Chuang VTG, Kinoshita R, Nishida K, Tanaka R, Enoki Y, Ishima Y, Kuniyasu A, Kobashigawa Y, Morioka H, Futaki S, Otagiri M, Maruyama T.

J Control Release. 2018 May 10;277:23-34. doi: 10.1016/j.jconrel.2018.02.037. Epub 2018 Mar 10.

PMID:
29530390
7.

Thioredoxin-albumin fusion protein prevents copper enhanced zinc-induced neurotoxicity via its antioxidative activity.

Tanaka KI, Shimoda M, Chuang VTG, Nishida K, Kawahara M, Ishida T, Otagiri M, Maruyama T, Ishima Y.

Int J Pharm. 2018 Jan 15;535(1-2):140-147. doi: 10.1016/j.ijpharm.2017.11.012. Epub 2017 Nov 6.

PMID:
29122608
8.

A novel S-sulfhydrated human serum albumin preparation suppresses melanin synthesis.

Ikeda M, Ishima Y, Kinoshita R, Chuang VTG, Tasaka N, Matsuo N, Watanabe H, Shimizu T, Ishida T, Otagiri M, Maruyama T.

Redox Biol. 2018 Apr;14:354-360. doi: 10.1016/j.redox.2017.10.007. Epub 2017 Oct 11.

9.

Long chain fatty acids alter the interactive binding of ligands to the two principal drug binding sites of human serum albumin.

Yamasaki K, Hyodo S, Taguchi K, Nishi K, Yamaotsu N, Hirono S, Chuang VTG, Seo H, Maruyama T, Otagiri M.

PLoS One. 2017 Jun 29;12(6):e0180404. doi: 10.1371/journal.pone.0180404. eCollection 2017.

10.

Improved anticancer effects of albumin-bound paclitaxel nanoparticle via augmentation of EPR effect and albumin-protein interactions using S-nitrosated human serum albumin dimer.

Kinoshita R, Ishima Y, Chuang VTG, Nakamura H, Fang J, Watanabe H, Shimizu T, Okuhira K, Ishida T, Maeda H, Otagiri M, Maruyama T.

Biomaterials. 2017 Sep;140:162-169. doi: 10.1016/j.biomaterials.2017.06.021. Epub 2017 Jun 22.

PMID:
28651144
11.

Crystallographic analysis of the ternary complex of octanoate and N-acetyl-l-methionine with human serum albumin reveals the mode of their stabilizing interactions.

Kawai A, Chuang VTG, Kouno Y, Yamasaki K, Miyamoto S, Anraku M, Otagiri M.

Biochim Biophys Acta Proteins Proteom. 2017 Aug;1865(8):979-984. doi: 10.1016/j.bbapap.2017.04.004. Epub 2017 May 1.

PMID:
28473296
12.

Apoptosis induction of poly-S-nitrosated human serum albumin in resistant solid tumor under hypoxia can be restored by phosphodiesterase 5 inhibition.

Ikeda M, Ishima Y, Chuang VTG, Ikeda T, Kinoshita R, Watanabe H, Ishida T, Otagiri M, Maruyama T.

Nitric Oxide. 2017 Sep 30;69:28-34. doi: 10.1016/j.niox.2017.04.005. Epub 2017 Apr 13.

PMID:
28414103
13.

Quantitative determination of polysulfide in albumins, plasma proteins and biological fluid samples using a novel combined assays approach.

Ikeda M, Ishima Y, Shibata A, Chuang VTG, Sawa T, Ihara H, Watanabe H, Xian M, Ouchi Y, Shimizu T, Ando H, Ukawa M, Ishida T, Akaike T, Otagiri M, Maruyama T.

Anal Chim Acta. 2017 May 29;969:18-25. doi: 10.1016/j.aca.2017.03.027. Epub 2017 Mar 22.

PMID:
28411626
14.

Human serum albumin hydropersulfide is a potent reactive oxygen species scavenger in oxidative stress conditions such as chronic kidney disease.

Shibata A, Ishima Y, Ikeda M, Sato H, Imafuku T, Chuang VTG, Ouchi Y, Abe T, Watanabe H, Ishida T, Otagiri M, Maruyama T.

Biochem Biophys Res Commun. 2016 Oct 21;479(3):578-583. doi: 10.1016/j.bbrc.2016.09.113. Epub 2016 Sep 23.

PMID:
27666483
15.

Evaluation of a new type of nano-sized carbon monoxide donor on treating mice with experimentally induced colitis.

Nagao S, Taguchi K, Miyazaki Y, Wakayama T, Chuang VT, Yamasaki K, Watanabe H, Sakai H, Otagiri M, Maruyama T.

J Control Release. 2016 Jul 28;234:49-58. doi: 10.1016/j.jconrel.2016.05.016. Epub 2016 May 9.

PMID:
27173944
16.

Renoprotective effect of long acting thioredoxin by modulating oxidative stress and macrophage migration inhibitory factor against rhabdomyolysis-associated acute kidney injury.

Nishida K, Watanabe H, Ogaki S, Kodama A, Tanaka R, Imafuku T, Ishima Y, Chuang VT, Toyoda M, Kondoh M, Wu Q, Fukagawa M, Otagiri M, Maruyama T.

Sci Rep. 2015 Sep 28;5:14471. doi: 10.1038/srep14471.

17.

S-Nitrosated human serum albumin dimer as novel nano-EPR enhancer applied to macromolecular anti-tumor drugs such as micelles and liposomes.

Kinoshita R, Ishima Y, Ikeda M, Kragh-Hansen U, Fang J, Nakamura H, Chuang VT, Tanaka R, Maeda H, Kodama A, Watanabe H, Maeda H, Otagiri M, Maruyama T.

J Control Release. 2015 Nov 10;217:1-9. doi: 10.1016/j.jconrel.2015.08.036. Epub 2015 Aug 22.

PMID:
26302904
18.

Pleiotropic Effects of Levofloxacin, Fluoroquinolone Antibiotics, against Influenza Virus-Induced Lung Injury.

Enoki Y, Ishima Y, Tanaka R, Sato K, Kimachi K, Shirai T, Watanabe H, Chuang VT, Fujiwara Y, Takeya M, Otagiri M, Maruyama T.

PLoS One. 2015 Jun 18;10(6):e0130248. doi: 10.1371/journal.pone.0130248. eCollection 2015.

19.

Direct radical scavenging activity of benzbromarone provides beneficial antioxidant properties for hyperuricemia treatment.

Kadowaki D, Sakaguchi S, Miyamoto Y, Taguchi K, Muraya N, Narita Y, Sato K, Chuang VT, Maruyama T, Otagiri M, Hirata S.

Biol Pharm Bull. 2015;38(3):487-92. doi: 10.1248/bpb.b14-00514. Epub 2015 Jan 15.

20.

Cross-linked human serum albumin dimer has the potential for use as a plasma-retaining agent for the fatty acid-conjugated antidiabetic drugs.

Taguchi K, Chuang VT, Yamasaki K, Urata Y, Tanaka R, Anraku M, Seo H, Kawai K, Maruyama T, Komatsu T, Otagiri M.

J Pharm Pharmacol. 2015 Feb;67(2):255-63. doi: 10.1111/jphp.12338. Epub 2014 Dec 31.

PMID:
25556343
21.

Therapeutic impact of human serum albumin-thioredoxin fusion protein on influenza virus-induced lung injury mice.

Tanaka R, Ishima Y, Enoki Y, Kimachi K, Shirai T, Watanabe H, Chuang VT, Maruyama T, Otagiri M.

Front Immunol. 2014 Nov 5;5:561. doi: 10.3389/fimmu.2014.00561. eCollection 2014.

22.

Polythiol-containing, recombinant mannosylated-albumin is a superior CD68+/CD206+ Kupffer cell-targeted nanoantioxidant for treatment of two acute hepatitis models.

Maeda H, Hirata K, Watanabe H, Ishima Y, Chuang VT, Taguchi K, Inatsu A, Kinoshita M, Tanaka M, Sasaki Y, Otagiri M, Maruyama T.

J Pharmacol Exp Ther. 2015 Feb;352(2):244-57. doi: 10.1124/jpet.114.219493. Epub 2014 Nov 14.

PMID:
25398242
23.

Biocompatible and mucoadhesive bacterial cellulose-g-poly(acrylic acid) hydrogels for oral protein delivery.

Ahmad N, Amin MC, Mahali SM, Ismail I, Chuang VT.

Mol Pharm. 2014 Nov 3;11(11):4130-42. doi: 10.1021/mp5003015. Epub 2014 Oct 7.

PMID:
25252107
24.

Nanoscale Diblock copolymer micelles: characterizations and estimation of the effective diffusion coefficients of biomolecules release through cylindrical diffusion model.

Amjad MW, Mohd Amin MC, Mahali SM, Katas H, Ismail I, Hassan MN, Chuang VT.

PLoS One. 2014 Aug 18;9(8):e105234. doi: 10.1371/journal.pone.0105234. eCollection 2014.

25.

Albumin fusion prolongs the antioxidant and anti-inflammatory activities of thioredoxin in mice with acetaminophen-induced hepatitis.

Tanaka R, Ishima Y, Maeda H, Kodama A, Nagao S, Watanabe H, Chuang VT, Otagiri M, Maruyama T.

Mol Pharm. 2014 Apr 7;11(4):1228-38. doi: 10.1021/mp400690v. Epub 2014 Mar 10.

PMID:
24576052
26.

Differential effects of methoxy group on the interaction of curcuminoids with two major ligand binding sites of human serum albumin.

Sato H, Chuang VT, Yamasaki K, Yamaotsu N, Watanabe H, Nagumo K, Anraku M, Kadowaki D, Ishima Y, Hirono S, Otagiri M, Maruyama T.

PLoS One. 2014 Feb 3;9(2):e87919. doi: 10.1371/journal.pone.0087919. eCollection 2014.

27.

Cys34-cysteinylated human serum albumin is a sensitive plasma marker in oxidative stress-related chronic diseases.

Nagumo K, Tanaka M, Chuang VT, Setoyama H, Watanabe H, Yamada N, Kubota K, Tanaka M, Matsushita K, Yoshida A, Jinnouchi H, Anraku M, Kadowaki D, Ishima Y, Sasaki Y, Otagiri M, Maruyama T.

PLoS One. 2014 Jan 8;9(1):e85216. doi: 10.1371/journal.pone.0085216. eCollection 2014.

28.

Albumin fusion renders thioredoxin an effective anti-oxidative and anti-inflammatory agent for preventing cisplatin-induced nephrotoxicity.

Kodama A, Watanabe H, Tanaka R, Kondo M, Chuang VT, Wu Q, Endo M, Ishima Y, Fukagawa M, Otagiri M, Maruyama T.

Biochim Biophys Acta. 2014 Mar;1840(3):1152-62. doi: 10.1016/j.bbagen.2013.12.007. Epub 2013 Dec 19.

PMID:
24361613
29.

Photoaffinity labeling of plasma proteins.

Chuang VT, Otagiri M.

Molecules. 2013 Nov 8;18(11):13831-59. doi: 10.3390/molecules181113831. Review.

30.

Albumin-drug interaction and its clinical implication.

Yamasaki K, Chuang VT, Maruyama T, Otagiri M.

Biochim Biophys Acta. 2013 Dec;1830(12):5435-43. doi: 10.1016/j.bbagen.2013.05.005. Epub 2013 May 10. Review.

PMID:
23665585
31.

Redox properties of serum albumin.

Anraku M, Chuang VT, Maruyama T, Otagiri M.

Biochim Biophys Acta. 2013 Dec;1830(12):5465-72. doi: 10.1016/j.bbagen.2013.04.036. Epub 2013 May 3. Review.

PMID:
23644037
32.

Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced pulmonary fibrosis progression.

Tanaka R, Watanabe H, Kodama A, Chuang VT, Ishima Y, Hamasaki K, Tanaka K, Mizushima T, Otagiri M, Maruyama T.

J Pharmacol Exp Ther. 2013 May;345(2):271-83. doi: 10.1124/jpet.112.201814. Epub 2013 Feb 26.

PMID:
23442250
33.

Albumin domain II mutant with high bilirubin binding affinity has a great potential as serum bilirubin excretion enhancer for hyperbilirubinemia treatment.

Minomo A, Ishima Y, Chuang VT, Suwa Y, Kragh-Hansen U, Narisoko T, Morioka H, Maruyama T, Otagiri M.

Biochim Biophys Acta. 2013 Apr;1830(4):2917-23. doi: 10.1016/j.bbagen.2013.01.006. Epub 2013 Jan 15.

PMID:
23328494
34.

A human serum albumin-thioredoxin fusion protein prevents experimental contrast-induced nephropathy.

Kodama A, Watanabe H, Tanaka R, Tanaka H, Chuang VT, Miyamoto Y, Wu Q, Endo M, Hamasaki K, Ishima Y, Fukagawa M, Otagiri M, Maruyama T.

Kidney Int. 2013 Mar;83(3):446-54. doi: 10.1038/ki.2012.429. Epub 2013 Jan 2.

35.

Effect of acetaminophen on the progression of renal damage in adenine induced renal failure model rats.

Kadowaki D, Sumikawa S, Arimizu K, Taguchi K, Kitamura K, Ishitsuka Y, Narita Y, Irie T, Chuang VT, Maruyama T, Otagiri M, Hirata S.

Life Sci. 2012 Dec 17;91(25-26):1304-8. doi: 10.1016/j.lfs.2012.09.018. Epub 2012 Oct 12.

PMID:
23069583
36.

Levoleucovorin as replacement for leucovorin in cancer treatment.

Chuang VT, Suno M.

Ann Pharmacother. 2012 Oct;46(10):1349-57. doi: 10.1345/aph.1Q677. Epub 2012 Oct 2. Review.

PMID:
23032661
37.

A uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropionate induces cell damage to proximal tubular cells via the generation of a radical intermediate.

Miyamoto Y, Iwao Y, Mera K, Watanabe H, Kadowaki D, Ishima Y, Chuang VT, Sato K, Otagiri M, Maruyama T.

Biochem Pharmacol. 2012 Nov 1;84(9):1207-14. doi: 10.1016/j.bcp.2012.07.033. Epub 2012 Aug 4.

PMID:
22898098
38.

Arginine 485 of human serum albumin interacts with the benzophenone moiety of ketoprofen in the binding pocket of subdomain III A and III B.

Kaneko K, Chuang VT, Ito T, Suenaga A, Watanabe H, Maruyama T, Otagiri M.

Pharmazie. 2012 May;67(5):414-8.

PMID:
22764574
39.

Pharmaceutical aspects of the recombinant human serum albumin dimer: structural characteristics, biological properties, and medical applications.

Taguchi K, Chuang VT, Maruyama T, Otagiri M.

J Pharm Sci. 2012 Sep;101(9):3033-46. doi: 10.1002/jps.23181. Epub 2012 May 9. Review.

PMID:
22573538
40.

Biological characteristics of two lysines on human serum albumin in the high-affinity binding of 4Z,15Z-bilirubin-IXα revealed by phage display.

Minomo A, Ishima Y, Kragh-Hansen U, Chuang VT, Uchida M, Taguchi K, Watanabe H, Maruyama T, Morioka H, Otagiri M.

FEBS J. 2011 Nov;278(21):4100-11. doi: 10.1111/j.1742-4658.2011.08316.x. Epub 2011 Sep 23.

41.

Human serum albumin-thioredoxin fusion protein with long blood retention property is effective in suppressing lung injury.

Furukawa M, Tanaka R, Chuang VT, Ishima Y, Taguchi K, Watanabe H, Maruyama T, Otagiri M.

J Control Release. 2011 Sep 5;154(2):189-95. doi: 10.1016/j.jconrel.2011.05.013. Epub 2011 May 17.

PMID:
21620911
42.

Histidine146 of human serum albumin plays a prominent role at the interface of subdomains IA and IIA in allosteric ligand binding.

Kaneko K, Chuang VT, Minomo A, Yamasaki K, Bhagavan NV, Maruyama T, Otagiri M.

IUBMB Life. 2011 Apr;63(4):277-85. doi: 10.1002/iub.457.

43.

Albumin fusion of thioredoxin--the production and evaluation of its biological activity for potential therapeutic applications.

Ikuta S, Chuang VT, Ishima Y, Nakajou K, Furukawa M, Watanabe H, Maruyama T, Otagiri M.

J Control Release. 2010 Oct 1;147(1):17-23. doi: 10.1016/j.jconrel.2010.05.020. Epub 2010 Jun 2.

PMID:
20678999
44.

Updates on contemporary protein binding techniques.

Chuang VT, Maruyama T, Otagiri M.

Drug Metab Pharmacokinet. 2009;24(4):358-64.

45.

Pharmaceutically important pre- and posttranslational modifications on human serum albumin.

Otagiri M, Chuang VT.

Biol Pharm Bull. 2009 Apr;32(4):527-34. Review.

46.

Recombinant human serum albumin.

Chuang VT, Otagiri M.

Drugs Today (Barc). 2007 Aug;43(8):547-61. Review.

PMID:
17925886
47.

Subdomain IIIA of dog albumin contains a binding site similar to site II of human albumin.

Kaneko K, Fukuda H, Chuang VT, Yamasaki K, Kawahara K, Nakayama H, Suenaga A, Maruyama T, Otagiri M.

Drug Metab Dispos. 2008 Jan;36(1):81-6. Epub 2007 Oct 9.

PMID:
17925384
48.

Recombinant human serum albumin dimer has high blood circulation activity and low vascular permeability in comparison with native human serum albumin.

Matsushita S, Chuang VT, Kanazawa M, Tanase S, Kawai K, Maruyama T, Suenaga A, Otagiri M.

Pharm Res. 2006 May;23(5):882-91. Epub 2006 May 16.

PMID:
16715378
49.

Stereoselective binding of human serum albumin.

Chuang VT, Otagiri M.

Chirality. 2006 Feb;18(3):159-66. Review.

PMID:
16432913
50.

Characterization of benzodiazepine binding site on human alpha1-acid glycoprotein using flunitrazepam as a photolabeling agent.

Chuang VT, Hijioka M, Katsuki M, Nishi K, Hara T, Kaneko K, Ueno M, Kuniyasu A, Nakayama H, Otagiri M.

Biochim Biophys Acta. 2005 Oct 10;1725(3):385-93. Epub 2005 Jun 8.

PMID:
15978731

Supplemental Content

Loading ...
Support Center